Limits...
Detection of residual rifampicin in urine via fluorescence quenching of gold nanoclusters on paper.

Chatterjee K, Kuo CW, Chen A, Chen P - J Nanobiotechnology (2015)

Bottom Line: The decreased fluorescence intensity of BSA-Au NCs in the presence of rifampicin allows for the sensitive detection of rifampicin in a range from 0.5 to 823 µg/mL.The detection limit for rifampicin was measured as 70 ng/mL.We have developed a robust, cost-effective, and portable point-of-care medical diagnostic platform for the detection of rifampicin in urine based on the ability of rifampicin to quench the fluorescence of immobilized BSA-Au NCs on wax-printed papers.

View Article: PubMed Central - PubMed

Affiliation: Department of Engineering and System Science, National Tsing Hua University, Hsinchu, 300, Taiwan. sanu.hit@gmail.com.

ABSTRACT

Background: Rifampicin or rifampin (R) is a common drug used to treat inactive meningitis, cholestatic pruritus and tuberculosis (TB), and it is generally prescribed for long-term administration under regulated dosages. Constant monitoring of rifampicin is important for controlling the side effects and preventing overdose caused by chronic medication. In this study, we present an easy to use, effective and less costly method for detecting residual rifampicin in urine samples using protein (bovine serum albumin, BSA)-stabilized gold nanoclusters (BSA-Au NCs) adsorbed on a paper substrate in which the concentration of rifampicin in urine can be detected via fluorescence quenching. The intensity of the colorimetric assay performed on the paper-based platforms can be easily captured using a digital camera and subsequently analyzed.

Results: The decreased fluorescence intensity of BSA-Au NCs in the presence of rifampicin allows for the sensitive detection of rifampicin in a range from 0.5 to 823 µg/mL. The detection limit for rifampicin was measured as 70 ng/mL. The BSA-Au NCs were immobilized on a wax-printed paper-based platform and used to conduct real-time monitoring of rifampicin in urine.

Conclusion: We have developed a robust, cost-effective, and portable point-of-care medical diagnostic platform for the detection of rifampicin in urine based on the ability of rifampicin to quench the fluorescence of immobilized BSA-Au NCs on wax-printed papers. The paper-based assay can be further used for the detection of other specific analytes via surface modification of the BSA in BSA-Au NCs and offers a useful tool for monitoring other diseases.

No MeSH data available.


Related in: MedlinePlus

a Absorption spectra of BSA-Au NCs (0.1× dilution) in the absence and presence of 10 µM rifampicin. b Fluorescence emission spectra (excitation wavelength at 480 nm) of BSA-Au NCs (0.1× dilution) in the absence and presence of 10 µM rifampicin.
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4482266&req=5

Fig2: a Absorption spectra of BSA-Au NCs (0.1× dilution) in the absence and presence of 10 µM rifampicin. b Fluorescence emission spectra (excitation wavelength at 480 nm) of BSA-Au NCs (0.1× dilution) in the absence and presence of 10 µM rifampicin.

Mentions: Au is conjugated with BSA through covalent bonding between the Au and thiol groups of the cysteine in BSA [41]. Rifampicin does not substitute the BSA and drive Au NC aggregation, which is evident from the MALDI-MS and ICP-MS data. Moreover, the absorption spectra indicate that aggregation did not occur, even after a long period of time following the addition of rifampicin to BSA-Au NCs (Figure 2a). However, the interaction of BSA and rifampicin has been previously reported [36]. Therefore, BSA-Au NC quenching by rifampicin (Figure 2b) may have been caused by the interaction of BSA and rifampicin, which changes the environment of the Au NCs. Changes in the absorption spectra of BSA-Au NCs in the presence of rifampicin (shown in Figure 2a) are similar to those reported for the interaction of BSA and rifampicin alone [36]. The absence of aggregated Au NCs without BSA protection corroborates the formation of structures similar to the rifampicin-RS-Au bonds.Figure 2


Detection of residual rifampicin in urine via fluorescence quenching of gold nanoclusters on paper.

Chatterjee K, Kuo CW, Chen A, Chen P - J Nanobiotechnology (2015)

a Absorption spectra of BSA-Au NCs (0.1× dilution) in the absence and presence of 10 µM rifampicin. b Fluorescence emission spectra (excitation wavelength at 480 nm) of BSA-Au NCs (0.1× dilution) in the absence and presence of 10 µM rifampicin.
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4482266&req=5

Fig2: a Absorption spectra of BSA-Au NCs (0.1× dilution) in the absence and presence of 10 µM rifampicin. b Fluorescence emission spectra (excitation wavelength at 480 nm) of BSA-Au NCs (0.1× dilution) in the absence and presence of 10 µM rifampicin.
Mentions: Au is conjugated with BSA through covalent bonding between the Au and thiol groups of the cysteine in BSA [41]. Rifampicin does not substitute the BSA and drive Au NC aggregation, which is evident from the MALDI-MS and ICP-MS data. Moreover, the absorption spectra indicate that aggregation did not occur, even after a long period of time following the addition of rifampicin to BSA-Au NCs (Figure 2a). However, the interaction of BSA and rifampicin has been previously reported [36]. Therefore, BSA-Au NC quenching by rifampicin (Figure 2b) may have been caused by the interaction of BSA and rifampicin, which changes the environment of the Au NCs. Changes in the absorption spectra of BSA-Au NCs in the presence of rifampicin (shown in Figure 2a) are similar to those reported for the interaction of BSA and rifampicin alone [36]. The absence of aggregated Au NCs without BSA protection corroborates the formation of structures similar to the rifampicin-RS-Au bonds.Figure 2

Bottom Line: The decreased fluorescence intensity of BSA-Au NCs in the presence of rifampicin allows for the sensitive detection of rifampicin in a range from 0.5 to 823 µg/mL.The detection limit for rifampicin was measured as 70 ng/mL.We have developed a robust, cost-effective, and portable point-of-care medical diagnostic platform for the detection of rifampicin in urine based on the ability of rifampicin to quench the fluorescence of immobilized BSA-Au NCs on wax-printed papers.

View Article: PubMed Central - PubMed

Affiliation: Department of Engineering and System Science, National Tsing Hua University, Hsinchu, 300, Taiwan. sanu.hit@gmail.com.

ABSTRACT

Background: Rifampicin or rifampin (R) is a common drug used to treat inactive meningitis, cholestatic pruritus and tuberculosis (TB), and it is generally prescribed for long-term administration under regulated dosages. Constant monitoring of rifampicin is important for controlling the side effects and preventing overdose caused by chronic medication. In this study, we present an easy to use, effective and less costly method for detecting residual rifampicin in urine samples using protein (bovine serum albumin, BSA)-stabilized gold nanoclusters (BSA-Au NCs) adsorbed on a paper substrate in which the concentration of rifampicin in urine can be detected via fluorescence quenching. The intensity of the colorimetric assay performed on the paper-based platforms can be easily captured using a digital camera and subsequently analyzed.

Results: The decreased fluorescence intensity of BSA-Au NCs in the presence of rifampicin allows for the sensitive detection of rifampicin in a range from 0.5 to 823 µg/mL. The detection limit for rifampicin was measured as 70 ng/mL. The BSA-Au NCs were immobilized on a wax-printed paper-based platform and used to conduct real-time monitoring of rifampicin in urine.

Conclusion: We have developed a robust, cost-effective, and portable point-of-care medical diagnostic platform for the detection of rifampicin in urine based on the ability of rifampicin to quench the fluorescence of immobilized BSA-Au NCs on wax-printed papers. The paper-based assay can be further used for the detection of other specific analytes via surface modification of the BSA in BSA-Au NCs and offers a useful tool for monitoring other diseases.

No MeSH data available.


Related in: MedlinePlus